American Association for Cancer Research
10780432ccr182439-sup-206067_4_supp_5425661_pp0xhp.docx (358.69 kB)

Supplementary Data from Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non–Small Cell Lung Cancer Patients

Download (358.69 kB)
journal contribution
posted on 2023-03-31, 21:00 authored by Christine M. Lusk, Donovan Watza, Greg Dyson, Douglas Craig, Valerie Ratliff, Angela S. Wenzlaff, Fulvio Lonardo, Aliccia Bollig-Fischer, Gerold Bepler, Kristen Purrington, Shirish Gadgeel, Ann G. Schwartz

Tables S1-S6 and Figures S1-S3.





Identifying novel driver genes and mutations in African American non–small cell lung cancer (NSCLC) cases can inform targeted therapy and improve outcomes for this traditionally underrepresented population. Tumor DNA, RNA, and germline DNA were collected from African American NSCLC patients who participated in research conducted at the Karmanos Cancer Institute (KCI) in Detroit, Michigan. Known mutations were ascertained through the Sequenom LungCarta panel of 214 mutations in 26 genes, RET/ROS1 fusions, amplification of FGFR1, and expression of ALK. Paired tumor and normal DNA was whole-exome sequenced for a subset of cases without known driver mutations. Of the 193 tumors tested, 77 known driver mutations were identified in 66 patients (34.2%). Sixty-seven of the 127 patients without a known driver mutation were sequenced. In 54 of these patients, 50 nonsynonymous mutations were predicted to have damaging effects among the 26 panel genes, 47 of which are not found in The Cancer Genome Atlas NSCLC white or African American samples. Analyzing the whole-exome sequence data using MutSig2CV identified a total of 88 genes significantly mutated at FDR q < 0.1. Only 5 of these genes were previously reported as oncogenic. These findings suggest that broader mutation profiling including both known and novel driver genes in African Americans with NSCLC will identify additional mutations that may be useful in treatment decision-making.